Gabriela Rozic-
Gabriela Rozic-
כתובת אימייל מאומתת בדומיין ariel.ac.il
כותרתצוטט על ידישנה
Ca2+-dependent splicing of neurexin IIα
G Rozic-Kotliroff, N Zisapel
Biochemical and biophysical research communications 352 (1), 226-230, 2007
442007
Dynamic changes in neurexins' alternative splicing: role of Rho-associated protein kinases and relevance to memory formation
G Rozic, Z Lupowitz, Y Piontkewitz, N Zisapel
PloS one 6 (4), e18579, 2011
222011
Exonal elements and factors involved in the depolarization-induced alternative splicing of neurexin 2
G Rozic, Z Lupowitz, N Zisapel
Journal of Molecular Neuroscience 50 (1), 221-233, 2013
162013
Translocation t (11; 14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
M Leiba, A Duek, N Amariglio, A Avigdor, N Benyamini, I Hardan, ...
Genes, Chromosomes and Cancer 55 (9), 710-718, 2016
122016
Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients
M Leiba, S Malkiel, I Budnik, G Rozic, A Avigdor, A Duek, A Nagler, ...
Blood Cells, Molecules, and Diseases 65, 1-7, 2017
112017
A multifunctional 5-aminolevulinic acid derivative induces erythroid differentiation of K562 human erythroleukemic cells
G Berkovitch-Luria, S Yakobovitch, M Weitman, A Nudelman, G Rozic, ...
European Journal of Pharmaceutical Sciences 47 (1), 206-214, 2012
82012
The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo
G Rozic, L Paukov, J Jakubikova, D Ben-Shushan, A Duek, A Leiba, ...
Oncotarget 7 (38), 62572, 2016
52016
Bi-functional prodrugs of 5-aminolevulinic acid and butyric acid increase erythropoiesis in anemic mice in an erythropoietin-independent manner
A Rephaeli, N Tarasenko, E Fibach, G Rozic, I Lubin, J Lipovetsky, ...
European Journal of Pharmaceutical Sciences 91, 91-97, 2016
42016
STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models
G Rozic, L Paukov, Z Cohen, I Shapira, A Duek, O Bejamini, A Avigdor, ...
Oncotarget 9 (59), 31367, 2018
22018
Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft
N Tarasenko, A Nudelman, G Rozic, SM Cutts, A Rephaeli
Investigational new drugs 35 (4), 412-426, 2017
22017
Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t …
A Duek, L Trakhtenbrot, N Amariglio, N Benyamini, I Zilbershats, C Ganzel, ...
Genes, Chromosomes and Cancer, 2019
2019
Monoallelic Deletion of the Whole Locus of Immunoglobulin Heavy Chain Gene [Del (IGH)] Is Associated with a Better Prognosis in Newly Diagnosed Multiple Myeloma
L Trakhtenbrot, A Duek, N Amariglio, A Avigdor, N Benyamini, I Hardan, ...
Blood 130 (Suppl 1), 5368-5368, 2017
2017
Compositions and methods for treating hematological malignancies
M Leiba, G Rozic
US Patent 9,782,387, 2017
2017
STK405759 As a Novel Tubulin Active Agent for Multiple Myeloma Therapy
G Rozic, P Lena, J Jakubikova, D Adrian, A Avigdor, A Nagler, M Leiba
Blood 126 (23), 5348-5348, 2015
2015
STK405759 as a novel drug for Multiple Myeloma therapy
G Rozic, J Jakubikova, L Paukov, A Duek, A Avigdor, A Nagler, M Leiba
Clinical Lymphoma, Myeloma and Leukemia 15, e234-e235, 2015
2015
THE NOVEL MOLECULE STK405759 HAS SELECTIVE CYTOTOXICITY AGAINST MULTIPLE MYELOMA IN VITRO AND IN VIVO
G Rozic, J Jakubikova, A Duek, A Avigdor, A Nagler, M Leiba
HAEMATOLOGICA 100, 500-500, 2015
2015
INVOLVEMENT OF SIGNAL TRANSDUCTION PATHWAYS IN ALTERNATIVE SPLICING OF NEUREXIN 2 IN BRAIN NEURONS
G Rozic, N Zisapel
NEUROPEPTIDES 43 (2), 173-174, 2009
2009
המערכת אינה יכולה לבצע את הפעולה כעת. נסה שוב מאוחר יותר.
מאמרים 1–17